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Abstract 42 
Context Size, encapsulation efficiency and stability affect the sustained release from 43 
nanoparticles containing protein-type drugs. 44 
Objectives Insulin was used to evaluate effects of formulation parameters on minimising 45 
diameter, maximising encapsulation efficiency and preserving blood glucose control 46 
following intraperitoneal (IP) administration.  47 
Methods Homogenisation or sonication was used to incorporate insulin into poly(D,L-48 
lactic-co-glycolic acid) (PLGA) nanoparticles with increasing PEG content.  Effects of 49 
polymer type, insulin/polymer loading ratio and stabiliser in the internal aqueous phase on 50 
physicochemical characteristics of NP, in vitro release and stability of encapsulated insulin 51 
were investigated. Entrapment efficiency and release were assessed by radioimmunoassay 52 
and bicinconnic acid protein assay, and stability was evaluated using SDS-PAGE. 53 
Bioactivity of insulin was assessed in streptozotocin-induced, insulin-deficient Type I 54 
diabetic mice. 55 
Results Increasing polymeric PEG increased encapsulation efficiency, whilst absence of 56 
internal stabiliser improved encapsulation and minimised burst release kinetics. 57 
Homogenisation was shown to be superior to sonication, with NP fabricated from 10% 58 
PEG-PLGA having higher insulin encapsulation, lower burst release and better stability. 59 
Insulin-loaded NP maintained normoglycaemia for 24 hours in diabetic mice following a 60 
single bolus, with no evidence of hypoglycaemia. 61 
Conclusions Insulin-loaded NP prepared from 10% PEG-PLGA possessed therapeutically 62 
useful encapsulation and release kinetics when delivered by the IP route. 63 
 64 
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1. Introduction 68 
Effective insulin administration underpins clinical management of Type 1 diabetes (1).  69 
Daily routines of insulin injection are a familiar feature, the discomfort of which 70 
contributes in part to poor patient adherence to prescribed therapy (2).  Although insulin is 71 
the most common treatment option for the Type 1 diabetic patient, its use is commonplace 72 
in therapy of the Type 2 patient, who suffers uncontrolled blood glucose levels 73 
unresponsive to diet, exercise, weight control and oral hypoglycaemic medication (3).  74 
Advances in formulation design that incorporate insulin are wide-ranging and form 75 
the basis of generic protein-based therapeutics (4).  Polymeric nanoparticles (NP) feature 76 
often and are used to incorporate an array of therapeutic peptides and proteins (5).  Their 77 
development is driven, in part, by excellent safety profiles relevant to human use (6).  78 
Biodegradable poly(esters), such as poly(D,L-lactic-co-glycolic acid)  (PLGA), are popular 79 
matrix materials and often modified by co-polymerisation with poly(ethylene glycol) 80 
(PEG).  This alters hydrophobicity, enhances the drug loading, controls the burst effect, 81 
prolongs in vivo circulation time by avoiding phagocytosis and, consequently, improves 82 
overall bioavailability (7).  These polymers have been used to encapsulate inter alia 83 
lysozyme, recombinant human epidermal growth factor and luteinising hormone-releasing 84 
hormone agonist, leading to improvement of pharmacokinetic profiles and minimising 85 
frequency of administration (8, 9).  They are generally fabricated using emulsion solvent 86 
evaporation or solvent-displacement techniques, which rely on primary and secondary 87 
emulsion phases of either organic or aqueous character (10).   88 
Studies describing encapsulation of insulin into biodegradable polymeric devices 89 
highlight certain problems.  A poorly controlled initial release phase is commonplace and 90 
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leads to hypoglycaemic shock (11).  However, the primary concern is poor stability of 91 
insulin after exposure to formulation conditions present during the emulsification and 92 
solvent removal-based processes (12).  The primary emulsification phases are of particular 93 
concern (13).  Emulsification of the primary aqueous protein solution with an immiscible  94 
solvent, such as dichloromethane, facilitates protein aggregation at the aqueous–organic 95 
interfacial boundary (14).  The end result is incomplete release (15) or low encapsulation 96 
efficiencies (16). 97 
There is a need to improve the sustained release kinetics of insulin and biologically 98 
active peptides from biodegradable carriers, whilst preserving activity during fabrication.  99 
Formulation studies using potent peptides is often hampered given that available quantities 100 
of peptide are often low.  Using model drugs, such as insulin, is a common strategy which 101 
gathers preliminary data.  Formulation of insulin-loaded NP by the double-emulsion 102 
technique is commonly done by shearing the system with either sonication or 103 
homogenisation (17).  Encapsulating insulin using sonication gives high insulin burst 104 
release and low entrapment efficiency as troublesome consequences (18).  Emulsification 105 
using homogenising maintains a linear release profile and higher encapsulation efficiency 106 
of hydrophilic drugs that cannot be achieved in particles fabricated by sonication (17), but 107 
details of stability are less well documented.  Therefore, in this study, sustained release NP 108 
for parenteral insulin delivery were evaluated for stability and biological activity during 109 
both fabrication steps and release.  The formulation strategy used was a modified double-110 
emulsion solvent evaporation technique adopting either homogenisation or sonication to 111 
optimise the entrapment efficiency and the initial release of insulin from PLGA and its 112 
diblock copolymers containing 5% and 10% PEG.  The effect of polymer type, 113 
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insulin/polymer loading ratio and concentration of poly(vinyl alcohol) in the internal 114 
aqueous phase, on the physicochemical characteristics of insulin-loaded NP, together with 115 
in vitro release profiles and stability were investigated.  Furthermore, we evaluated in vivo 116 
insulin activity using the IP route, as administration is relatively straightforward in the 117 
murine model.  It is also relevant to the development of continuous intraperitoneal insulin 118 
infusion.  IP insulin has been shown to provide adequate glycaemic control, which appears 119 
superior to that seen following treatment with conventional SC insulin (19). However, the 120 
approach is not without its clinical difficulties and more data is needed to assess long-term 121 
safety, which will include evaluation of novel delivery strategies, such as nanoparticulate 122 
platforms (19). 123 
  124 
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2. Materials and Methods 125 
2.1 Materials 126 
PLGA (Resomer®RG 503H) with an average molecular weight of 34 kDa and a lactide-to-127 
glycolide ratio of 50:50 was purchased from Sigma Chemical Co. (St. Louis, USA).  Two 128 
PEG-PLGA diblock copolymers (Resomer® RGP d 5055 (5% PEG) and Resomer® RGP d 129 
50105 (10% PEG) with PEG molecular weight of 5 kDa, were purchased from Boehringer-130 
Ingelheim (Ingelheim, Germany).  Bovine insulin (51 amino acids, MW5.734 kDa), 131 
poly(vinyl alcohol) (PVA) 87-89% hydrolysed (MW 31.000-50.000) and phosphate 132 
buffered saline (PBS) were obtained from Sigma Chemical Co. (St. Louis, USA).  A Micro 133 
BCA® Kit was obtained from Pierce Ltd. (Rockford, IL).  Dichloromethane was of HPLC 134 
grade and all other reagents were of analytical grade or higher purity.  Milli-Q-water was 135 
used throughout the study. 136 
 137 
2.2 Preparation of insulin-loaded NP 138 
A modified, double-emulsion, solvent evaporation technique was used in this work, as 139 
illustrated schematically in Fig. 1 (20).  Insulin was dissolved in 0.2 ml of internal aqueous 140 
phase (0.1 M HCl), which was then emulsified at 6,000 rpm (Silverson L5T, Silverson 141 
Machines Ltd., Buckinghamshire, UK) for 2 minutes into 2.0 ml of dichloromethane 142 
(DCM) containing 10% w/v of the polymer type under investigation.  The primary 143 
emulsion (w/o) was injected directly into 50 ml of PVA solution (external aqueous phase) 144 
under agitation.  Emulsification continued at 10,000 rpm for 6 minutes to produce the 145 
secondary emulsion using the same homogeniser. 146 
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For insulin-loaded NP prepared by sonication, insulin was dissolved in 0.2 ml of 147 
0.1 M HCl and then mixed with 2.0 ml of DCM containing 10% w/v of 10% PEG-PLGA.  148 
The primary and secondary emulsification steps were performed using an ultrasonic 149 
processor equipped with a XL-2020 3.2 mm probe (Misonix Incorporated, NY, USA) in 150 
an ice bath for 2 minutes.  The emulsion was stirred overnight under vacuum to evaporate 151 
the DCM and prevent pore formation on the surface of the NP.  After formation, NP were 152 
collected by centrifugation at 10,000 x g for 30 minutes at 4 °C (Sigma Laborzentrifugen 153 
GmbH., Germany), washed three times with ultrapure water and 2% w/v sucrose solution 154 
and lyophilised using freeze drying (Labconco., Missouri, USA).  The freeze-dried NP 155 
were stored in a desiccator at ambient temperature.  The formulation variables and 156 
identifier codes are listed in Table 1. 157 
 158 
2.3 NP characterisation 159 
Freeze-dried NP samples (5.0 mg) were mixed with ultrapure water to a suitable 160 
concentration and suspended using vortex mixing for 3 minutes.  Particle size and its 161 
distribution (polydispersity index, PDI) were measured using dynamic light scattering 162 
(Zetasizer 5000, Malvern Instruments Ltd., Malvern, UK).  NP zeta potential was 163 
quantified using laser Doppler anemometry (Zetasizer 5000 (Malvern Instruments Ltd., 164 
Malvern, UK), following dispersal and adjustment of conductivity with 0.001 M KCl.  All 165 
measurements were performed in triplicate. 166 
The NP surface morphology was observed by scanning electron microscopy (SEM) 167 
(Quanta 400 FEG, FEI Ltd., Oregon USA).  An aliquot of NP was mounted on carbon tape 168 
and sputter-coated with gold under vacuum in an argon atmosphere before observation.  169 
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 170 
2.4 Determination of insulin loading and entrapment efficiency. 171 
Insulin loading was determined using a direct colorimetric method (20).  A weighed sample 172 
of NP was dissolved in 0.5 ml of 1.0 M NaOH and incubated overnight at 37 °C.  The 173 
solution was neutralised with 0.5 ml of 1.0 M HCl, centrifuged for 5 minutes at 10,000 x g 174 
and the supernatant analysed for insulin content using a bicinchoninic acid assay (Micro 175 
BCA®) (21).  Percentage entrapment efficiency (%EE) was expressed as a ratio of the 176 
determined insulin loading to the maximum theoretical loading.  An indirect 177 
radioimmunoassay method was used to determine insulin content in the supernatant phase 178 
during drug release analysis (22).  A standard curve of bovine insulin prepared over a 179 
concentration range of 3.9x10-3 to 2.0x101 ng ml-1 was used.     180 
 181 
2.5 In vitro release studies 182 
Lyophilised insulin-loaded NP (5.0 mg) were suspended in a release medium of 1.0 ml 183 
PBS (pH 7.4) and incubated at 37 °C using a reciprocal shaking water bath at a fixed speed 184 
of 100 rpm.  Samples (100 µl) were taken at predetermined time intervals of 1, 12, 24, 48, 185 
96, 120, 144 and 168 hours and replaced with fresh PBS at the same temperature.  The 186 
collected samples were centrifuged for 5 minutes at 10,000 x g and the insulin content in 187 
the supernatant determined using the indirect radioimmunoassay, as described in section 188 
2.4.  Each experiment was performed in triplicate. 189 
 190 
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2.6 Determination of residual PVA 191 
The residual mass of PVA attached to the NP surface after washing was determined by a 192 
colorimetric method based on the reaction with iodine.  A sample of freeze-dried NP (2.0 193 
mg) was incubated in 0.5 M NaOH for 15 minutes at 60 °C, neutralised by addition of 1.0 194 
M HCl and the final volume adjusted to 5.0 ml with water.  To each NP sample, 3.0 ml of 195 
iodine reagent (0.65 M solution of boric acid, 0.5 ml of a solution of I2/KI (0.05 M/0.15 196 
M)) and 1.5 ml of water were added.  The absorbance of each sample was measured using 197 
visible spectroscopy (Agilent 8453, Agilent Technologies, Palo Alto, CA, USA) at 690 nm 198 
after 15 minutes incubation and compared to a standard plot of known PVA concentration 199 
(23).  Residual PVA was expressed as a percentage mass fraction of the total NP mass. 200 
 201 
2.7 In vitro stability and protein integrity studies 202 
SDS-PAGE analysis was performed using a BioRad Mini Protean II gel apparatus 203 
(Hercules, CA, USA).  The final supernatant obtained after 7 days of the in vitro release 204 
experiment was used as a sample for this study.  The sample was prepared under non-205 
reducing conditions for application on a NuPAGE® gel consisting of 4% and 12% stacking 206 
and resolving gels, respectively.  A fixative solution of Coomassie Brilliant Blue was 207 
employed to stain and reveal the protein bands.  Insulin dispersed in PBS (pH 7.4) was 208 
used as control to simulate release conditions.  Electrophoresis was run in constant current 209 
mode (50 mA) and fixed voltage modes (60 V and 120 V) during stacking and running 210 
stages, respectively (24).  The GelDoc-It™ image system was used to record the position 211 
of protein bands. 212 
 213 
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2.8. In vivo studies  214 
 215 
Experimental animals 216 
Young (8-week-old) male National Institutes of Health Swiss mice (18–20 g) (Harlan, UK) 217 
were age matched, divided into four groups and housed individually in an air-conditioned 218 
room at 22±2 °C with a 12:12 hour light-dark cycle (08:00–20:00) and free access to a 219 
standard diet and water ad libitum.  To induce Type I diabetes, weight-matched mice 220 
received a single intraperitoneal injection of streptozotocin (STZ, 150 mg kg-1) dissolved 221 
in citrate buffer (pH 4.5).  Mice with fasting blood glucose level >8 mmol l-1 72 hours after 222 
STZ administration were considered diabetic and included in the study.  All animal 223 
experiments were carried out in accordance with the UK Animals (Scientific Procedures) 224 
Act of 1986 and Ulster University’s Animal Ethics Committee guidelines. 225 
 226 
In vivo bioactivity of insulin formulation 227 
Four groups (n=6) of insulin-deficient STZ-induced diabetic mice were used for this study.  228 
Insulin-loaded NP and free insulin were suspended in sterile PBS and injected 229 
intraperitoneally at a dose of 25 U kg-1 body weight.  The two control groups comprised 230 
mice treated with saline or blank NP.  Blood samples were withdrawn by tail vein puncture 231 
prior to injection and at predetermined time points thereafter.  Blood glucose and insulin 232 
were measured.  Blood glucose concentrations were determined instantaneously by the 233 
glucose oxidase method using a handheld Ascencia Counter meter (Bayer Healthcare, UK) 234 
(25), while plasma insulin was measured by radioimmunoassay (22), as described 235 
previously. 236 
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 237 
2.9 Statistical analysis 238 
Results are presented as mean ± SD and mean ± SEM for in vitro and in vivo studies, 239 
respectively.  Comparative analyses between groups were carried out using one-way 240 
analysis of variance (ANOVA) followed by Tukey’s post hoc test.  Area-under-the-curve 241 
(AUC) analysis was performed using the trapezoidal rule with baseline correction.  A value 242 
of p<0.05 was considered statistically significant. 243 
  244 
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3. Results and discussion 245 
3.1 Effect of polymer type on 9% insulin-loaded NP (F1, F4 and F7) 246 
The physicochemical characterisation of insulin-loaded NP fabricated with three different 247 
polymer types is shown in Table 1.  For an insulin loading of 9%, PEGylated NP (F4 and 248 
F7) prepared from 5% and 10% PEG-PLGA diblock copolymers, respectively, were 249 
significantly lower in size (p<0.05) than NP prepared from PLGA (F1).  This can be 250 
explained by the short chain length of PEG-PLGA compared to PLGA, as well as the 251 
presence of covalently linked hydrophilic PEG that decreased polymer association during 252 
NP formation, which eventually resulted in the formation of smaller particles (26).  All 253 
insulin-loaded NP formulations showed low PDI values ranging from 0.21 to 0.43.  254 
Increasing PEG content in the polymer backbone caused a further decrease in the NP size, 255 
leading to the smaller size of F7 compared to F4.  These results are in good agreement with 256 
previous reports (20). 257 
PLGA NP exhibited higher negative zeta potential values when compared to 258 
PEGylated NP (F4 and F7), but no significant difference between the two latter types was 259 
observed.  PEG chains on the NP surface are expected to mask surface charge arising from 260 
PLGA (7).  This reduction of surface charge is a drawback for the PEGylated types, given 261 
that NP are notoriously difficult to stabilise when dispersed or suspended in aqueous media.  262 
Attractive forces cause NP to agglomerate or aggregate, and surface charges play an 263 
important role in preventing this effect.  However, during this work, no discernible effects 264 
relating to aggregation were observed.  To obtain long-term stable NP samples, the 265 
dispersions were freeze-dried and NP were re-dispersed in a suitable medium prior to the 266 
in vitro or in vivo experiments. 267 
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PEGylation resulted in a significant increase (p<0.05) in insulin loading and 268 
encapsulation efficiency.  PEG-PLGA is an amphiphilic polymer and creates a benign 269 
environment for encapsulating hydrophilic molecules, like insulin, through its hydrophilic 270 
PEG chains.  This slows peptide diffusion to the external aqueous phase and results in high 271 
loading efficacy (27).  The higher encapsulation efficiency of F7 compared to F1 and F4 272 
is due to the lower solubility of 10% PEG-PLGA in DCM, which resulted in faster polymer 273 
precipitation that prevented insulin escape to the outer phase and consequently increased 274 
its entrapment efficiency (28). 275 
In vitro release profiles of F1, F4 and F7 are shown in Fig. 2.  Insulin-loaded NP 276 
prepared with PEGylated polymers displayed an initial burst release, followed by a steady 277 
release profile.  The burst release from insulin-loaded PLGA NP was smaller in comparison 278 
to PEGylated polymers, followed by a more sustained phase.  The burst release of insulin 279 
is associated with its peripheral loading, which enables it to diffuse quickly towards the 280 
release medium (29) and is more prevalent in the PEGylated types.  The burst release was 281 
faster and significantly higher from F4 and F7 when compared to F1 (p<0.05), with greater 282 
cumulative release after 24 hours.  Results showed sustained release of insulin from F1, 283 
whereas release from F4 and F7 approached complete release over a 7-day period.  The 284 
release of insulin from PEGylated NP is governed by its diffusion through a swollen inner 285 
structure formed after contact with the aqueous release medium due to the presence of 286 
hydrophilic PEG moieties in the polymer matrix (20). 287 
 288 
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3.2 Effect of insulin/polymer loading ratio 289 
The influence of insulin loading (9%, 6% and 3%) is captured in comparisons of 290 
formulations of PLGA (F1, F2 and F3), 5% PEG-PLGA (F4, F5 and F6) and 10% PEG-291 
PLGA (F7, F8 and F9).  Results from Lamprecht et al. (30) show that there is no effect of 292 
protein loading on NP size.  However, the results in this work showed that increasing 293 
insulin loading from 3% to 9% resulted in a significant increase (p<0.05) in the size of 294 
PLGA and PEGylated NP.  In addition, blank NP were significantly lower in size when 295 
compared to insulin-loaded types.  This is likely due to insulin in the primary emulsion 296 
droplets driving up their size, and insulin present on the NP surface, which together 297 
increases the mean NP diameter. 298 
Increasing the ratio of insulin to polymer had a significant effect on PDI values and 299 
encapsulation efficiency (p<0.05), but no effect on surface charge.  Importantly, the 300 
increase in insulin loading resulted in a significant decrease (p<0.05) in %EE.  Although 301 
this may at first seem counter-intuitive, it can be explained in terms of concentration 302 
gradients driving drug out of the primary droplets.  Increasing insulin concentration 303 
gradients in this way may deplete droplets of payload more effectively and dump free 304 
insulin into the continuous water phase (30). 305 
The in vitro release profiles and the initial bursts were directly related to the degree 306 
of theoretical insulin loading, as shown in Fig. 3, 4 and 5.  There was a positive correlation 307 
between insulin loading and the extent of the initial burst phase.  High insulin burst and 308 
rapid release rate could be attributed to the drug concentration gradient between the NP 309 
and the release media.  Moreover, the diffusion of surface-associated insulin facilitates the 310 
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formation of water-filled channels that allow subsequent elution of the core-residing insulin 311 
(31, 32). 312 
 313 
3.3 Effect of internal aqueous phase stabiliser concentration 314 
PVA was used as a stabilising agent in this study and set at three different concentrations, 315 
namely 0.00%, 1.25% and 2.50% w/v.  The resulting physicochemical properties of 316 
different NP formulations of PLGA (F3, F10 and F11), 5% PEG-PLGA (F6, F12 and F13) 317 
and 10% PEG-PLGA (F9, F14 and F15) are shown in Table 1.  The NP size was 318 
significantly decreased (p<0.01) by PVA addition to the primary emulsion.  Increasing 319 
PVA concentration caused further decreases in the mean NP size.  There are differing views 320 
in the literature on whether the primary or secondary emulsion phases have the greater 321 
influence on particle size.  It is proposed that PVA stabilises the inner water droplets against 322 
coalescence, which produces smaller primary emulsion droplets and resultantly smaller NP 323 
sizes (31).  However, this is in contrast to findings of Bilati et al. (33) who concludes that 324 
the secondary emulsification step effectively determines the final particle size in double-325 
emulsion techniques.  In this current study, particle size reduction was more significant in 326 
PEGylated NP when compared to PLGA NP (p<0.05).  Since PLGA is more hydrophobic 327 
than a diblock copolymer like PEG-PLGA, the interactions between PVA and PEGylated 328 
polymers will be stronger than those to PLGA alone.  Therefore, our results support the 329 
role of the primary emulsion on determining final particle size, especially if PEGylated 330 
polymers are used. 331 
PDI values were significantly decreased by adding PVA to the internal phase, 332 
whereas a negligible effect on the surface charge was observed.  Addition of internal phase 333 
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stabiliser had a no significant impact on the encapsulation efficiency in all types of NP, 334 
although a decreasing trend was observed.  This may be due to the decreasing particle size, 335 
resulting in a larger interfacial area for mass transfer (34).  These results are not observed 336 
in other work, which show a sharp increase in encapsulation efficiency by adding PVA (or 337 
other stabilisers), possibly by improved stabilisation of the primary emulsion (36) or 338 
payload-PVA interactions (31, 35).  Clearly, further detailed study is required to determine 339 
the exact effect of PVA on encapsulation efficiency. 340 
The effect of internal aqueous phase stabiliser on the insulin release from different 341 
NP formulations is shown in Fig. 6.  A significant increase (p<0.05) in the release rate after 342 
PVA addition was observed, and the amount of initial release also increased concomitantly.  343 
The in vitro release profile of F11, F13 and F15 with 2.5% w/v PVA was significantly 344 
faster than the release from NP prepared with 1.25% w/v PVA and NP without PVA.  Initial 345 
bursts of 49%, 61% and 68% were observed from F11, F13 and F15, respectively, 346 
compared to 27%, 42% and 43% from F3, F6 and F9, respectively.  The results in Fig. 6 347 
indicate that increasing PVA concentration increased the early stage release, possibly by 348 
way of enhanced peripheral accumulation of insulin close to the NP surface.  In addition, 349 
higher concentrations of PVA enable porosity to form in the NP matrix, which facilitates 350 
outwards diffusion of insulin (34, 36). 351 
 352 
3.4 Comparison between homogenisation and sonication 353 
In this work, minimising NP size and maximising %EE was considered as an outcome from 354 
optimisation of the formulation variables.  Formulation F9, which was prepared by 355 
homogenisation using 10% PEG-PLGA, contained NP that were significantly lower in size 356 
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and higher in %EE (P value <0.05) compared to formulations fabricated by other types of 357 
polymers under similar conditions.  This formulation was, therefore, chosen for 358 
comparison to methods that used sonication instead of homogenisation.  It is also important 359 
to note that these optimised NP (size < 400 nm and encapsulation efficiency > 90%) are 360 
clearly distinguishable from other published work, such as that of Liu et al. (37). 361 
Insulin-loaded NP (F16) prepared by sonication resulted in a decrease in %EE 362 
compared to NP prepared by homogenisation (F9).  Size and PDI values were significantly 363 
(p<0.01) higher.  The release profile of F16 showed significantly higher initial and higher 364 
total amounts of insulin released (p<0.05) when compared to similar data from F9 (Fig. 7).  365 
Release data for F9 and F16 follow a profile that is typical of drug delivery systems that 366 
display Higuchi kinetics.  Indeed, fitting cumulative percentage drug release data in Fig. 7 367 
to the square root of time (data not shown) confirmed this assumption.  368 
 369 
3.5 Scanning electron microscopy 370 
Fig. 8 shows a micrograph of the optimised insulin-loaded NP (F9).  NP were of spherical 371 
shape with a size distribution in approximate agreement with light scattering data.  The 372 
smooth NP surface was free from void and pores.  After 7 days of in vitro release, there 373 
was little evidence of the presence of spherical structures.  Instead, the recovered polymeric 374 
material was irregular and sheet-like (Fig. 8B).  As F9 has a high PEG content, pore 375 
formation during exposure to aqueous media is expected, which may explain poor retention 376 
of spherical shape and the enhanced release observed in Fig. 7 (20). 377 
 378 
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3.6 Residual PVA 379 
PVA is an emulsifier, widely used in the preparation of PLGA NP, and popular because of 380 
its ability to produce uniform NP with a size easily dispersed in aqueous media.  381 
Importantly, residual PVA associated with PLGA NP can modify their bio-382 
physicochemical properties (38).  The addition of PVA to the internal aqueous phase had 383 
no impact on the residual PVA attached to all types of NP.  Residual PVA determined in 384 
different types of NP was less than 7%, being higher for PEGylated NP (Fig. 9).  The higher 385 
adsorption of PVA to the surface of PEGylated NP is attributed to the amphiphilic 386 
characters of these polymers due to PEG chains, with possible PVA interaction.  The 387 
presence of PEG chains increases the surface area of the NP and consequently increase the 388 
probability of hydrophilic molecules, like PVA, to attach to its surface (39).  These results 389 
contradict those of others (29) who found a reduction in PVA adsorption when PEG is used 390 
to modify PLA during NP formation.  Thus, it is clear that the alteration in NP surface 391 
hydrophilicity using co-polymerised PEG does not produce a clear trend when PVA 392 
adsorption is considered. 393 
 394 
3.7 In vitro stability and protein integrity 395 
Preserving secondary and tertiary structures of proteins and peptides is essential in 396 
maintaining therapeutic efficacy.  Stability issues are affected by different formulation 397 
conditions with attention focused on the harsh fabrication stress employed during 398 
emulsification-based methods (40).  Encapsulation of insulin using the double-emulsion 399 
technique enables it to act as a surface active molecule, which tends to adsorb at the primary 400 
emulsion water/oil interfaces.  This adsorption may lead to instability by unfolding, 401 
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inactivation or irreversible aggregation.  In addition, the high shear stress used for effective 402 
emulsification may influence the three-dimensional structure of insulin, which is essential 403 
for its therapeutic activity (41). 404 
Aggregation is a major concern for protein-loaded PLGA microspheres, caused by 405 
the acidic environment when polymer degradation products accumulate during the release 406 
phase (42).  To investigate the possibility of insulin aggregation after formulation and in 407 
vitro release, the integrity of the insulin released after seven days was evaluated.  The three 408 
single lines in the gels (Fig. 10), representing the insulin band of the naked and 409 
encapsulated insulin released from F9 and F16, provided evidence that the entrapped 410 
insulin did not suffer any significant aggregation during its formulation and after in vitro 411 
release (36).  Although use of a stability indicating method, such as HPLC, would highlight 412 
possible degradation, quantification by radioimmunoassay in this work supported the lack 413 
of degradation or aggregation of encapsulated insulin.  This stability is attributed to co-414 
polymerised PEG, which prevents an acidic micro-environment within particulate systems 415 
(43).  Furthermore, the hydrophobicity of the PLGA surface is masked by PEG, reducing 416 
insulin re-adsorption and preventing possible aggregation (44).  Both insulin-loaded NP 417 
prepared by homogenisation or sonication maintained insulin integrity after fabrication and 418 
in vitro release. 419 
 420 
3.8 In vivo bioactivity 421 
It is well-documented that formulation steps inactivate or otherwise denature a proportion 422 
of encapsulated insulin (45).  If this occurs, then bioactivity is compromised and careful in 423 
vivo assessment is required.  Therefore, in this work, we determined the bioactivity of an 424 
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optimised NP formulation in insulin-deficient Type 1 diabetic mice.  The effect of a single 425 
intraperitoneal injection of (25 U kg-1) of free insulin and insulin-loaded NP (F9) on blood 426 
glucose levels in type I diabetic mice is shown in Fig. 11A-11C.  Free insulin significantly 427 
decreased plasma glucose (P <0.001) directly after injection, compared to the blank NP 428 
and saline groups.  Blood glucose concentrations decreased by 69.1% (P <0.001) 2 hours 429 
after administration.  However, following this initial reduction, blood glucose 430 
concentrations in free insulin-injected mice returned rapidly to control diabetic levels.  This 431 
is in accordance with the short half-life of parenterally delivered insulin (20). 432 
Insulin-loaded NP induced a significant and sustained glucose lowering effect, as 433 
expected from in vitro release data.  At the 2-hour time point, insulin-loaded NP had 434 
reduced blood glucose levels by 48.3% in our Type 1 diabetic subjects, and these mice had 435 
significantly lower glucose levels compared to free insulin-treated mice at 3 hours, post-436 
injection.  The clear difference between the glycaemic statuses of the two groups of mice 437 
was apparent throughout the entire 24-hour observation period, highlighted by significantly 438 
lowered blood glucose concentrations in mice treated with insulin-loaded NP at 24 hours.  439 
Encouragingly, blood glucose levels remained within the normal range in insulin-loaded 440 
NP treated mice (5-7 mmol l-1) throughout the 24-hour period, with no obvious signs of 441 
hypoglycaemia.  This is a foremost advantage for any insulin-containing formulation (20).  442 
Our results showed a clear effect on blood glucose concentration, which is in contrast to 443 
the results of Liu et al. (37), who showed insignificant decreases in blood glucose levels 444 
following insulin-loaded NP administration within the first 12 hours. 445 
Plasma insulin profiles closely mirrored blood glucose levels in all groups of mice, 446 
confirming that the initial burst release and subsequent sustained release of insulin for the 447 
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NP were key features of the improved glycaemic status (20).  Plasma insulin levels in mice 448 
injected with free insulin (Fig. 12A) revealed a mean peak for plasma insulin concentration 449 
(Cmax) of 21.3 ng ml
-1 observed after one hour, with levels returning to basal, 3 hours after 450 
administration.  Mice injected with insulin-loaded NP showed a peak insulin concentration 451 
of 14.5 ng ml-1, which occurred 3 hours after injection and was significantly (P <0.001) 452 
higher than the free insulin group.  Plasma insulin levels remained elevated in insulin-453 
loaded NP treated mice, and were still significantly (P<0.01) greater than free insulin 454 
injected mice 24 hours post-injection.  AUC analysis (Fig. 11C and 12A) confirmed the 455 
sustained and enhanced bioactive profile of released insulin, confirming preservation of its 456 
biological activity.  Although further studies are required, it is feasible that the remaining 457 
insulin within the NP (over 50%) would be slowly released to further sustain 458 
normoglycaemic status beyond 24 hours. 459 
 460 
4. Conclusions 461 
The aqueous solubility of insulin hinders entrapment efficiency and gives rise to a 462 
pronounced burst release from particulate systems.  High encapsulation efficiency, low 463 
initial release and maintaining stability are essential requirements for sustained insulin 464 
delivery from biodegradable formulations.  In this current study, we modified key features 465 
of the double emulsion technique, such as pH of the internal phase, the ratio of internal 466 
phase to external phase and homogenisation speed.  After optimisation of the formulation 467 
conditions, the %EE of insulin reached 91.5% and the burst release within the first 24 hours 468 
was restricted to 28%.  An optimised insulin-loaded NP was fabricated by homogenisation 469 
from 10% PEG-PLGA with low insulin loading and without any surfactants in the primary 470 
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emulsion.  Insulin-loaded NP prepared by homogenisation showed lower particle size, 471 
lower PDI, higher encapsulation efficiency and lower initial release compared to NP 472 
prepared by sonication.  PEGylated (10%) PLGA polymer exerted a protective effect on 473 
insulin stability by suppressing adsorption phenomena and preventing insulin aggregation.  474 
The optimised insulin-loaded NP controlled in vitro insulin release for 168 hours.  Both in 475 
vitro and in vivo data were in close agreement.  Intraperitoneal administration showed 476 
effective and pronounced glycaemic control, which verified preservation of biological 477 
activity and confirmed the sustained release profiles determined during release studies. 478 
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Table 1.  Formulation variables for insulin nanoparticles 
Formulation ID  Polymer type  
Insulin 
loading 
(w/w %)  
Internal aqueous 
phase PVA 
concentration 
(% w/v)  
Size 
(nm) 
*PDI 
Zeta potential 
(mV) 
%EE 
        
Homogenisation        
F1  PLGA  9  0.00 396.5±20.9 0.43±0.05 -21.98±2.82 42.89±3.01 
F2  PLGA  6  0.00 357.0±14.4 0.36±0.01 -20.15±1.96 56.73±3.45 
F3  PLGA  3  0.00 322.5±15.0 0.29±0.02 -20.03±0.95 70.33±5.99 
F4  5%PEG-PLGA  9  0.00 357.5±14.4 0.39±0.06 -6.11±1.04 52.17±3.02 
F5  5% PEG-PLGA  6  0.00 310.3±16.7 0.32±0.11 -5.66±1.53 68.89±3.28 
F6  5% PEG-PLGA  3  0.00 273.5±8.5 0.25±0.01 -6.21±1.91 80.84±4.23 
F7  10%PEG-PLGA  9  0.00 317.5±16.5 0.40±0.04 -5.21±0.98 61.18±3.82 
F8  10%PEG-PLGA  6  0.00 272.5±17. 0.33±0.01 -6.05±1.85 73.88±4.16 
F9  10%PEG-PLGA  3  0.00 239.3±13.0 0.25±0.03 -5.36±1.70 91.52±4.59 
F10  PLGA  3  1.25 300.5±11.8 0.22±0.01 -19.26±1.47 63.76±3.06 
F11  PLGA  3  2.50  277.5±14.7 0.21±0.01 -20.15±1.69 61.66±2.87 
F12  5%PEG-PLGA  3  1.25  240.8±15.1 0.21±0.02 -5.76±0.72 74.39±2.79 
F13  5%PEG-PLGA  3  2.50  200.3±8.5 0.22±0.01 -5.91±1.12 71.23±5.27 
F14  10%PEG-PLGA  3  1.25  197.5±6.8 0.21±0.02 -5.41±0.83 82.45±5.08 
F15  10%PEG-PLGA  3  2.50  160.0±15.7 0.21±0.01 -5.80±1.06 80.88±5.42 
Blank NP PLGA  0 0.00 269.5±13.5 0.31±0.06 -19.58±1.78 - 
Blank NP 5%PEG-PLGA  0 0.00 211.5±17.6 0.24±0.07 -6.77±0.97 - 
Blank NP 10%PEG-PLGA  0 0.00 187.8±9.8 0.21±0.04 -5.01±1.43 - 
        
Sonication        
F16  10%PEG-PLGA  3  0.00 283.8±16.3 0.40±0.05 -5.93±1.33 84.01±5.72 
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*polydispersity index 
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Fig. 12 
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Legend to Figures 
Fig. 1.  Sequence of steps comprising the double-emulsion, solvent evaporation technique.  The 
factors investigated in this study were the insulin concentration, polymer type and PVA 
concentration in the primary emulsion.  
 
Fig. 2.  In vitro release profiles of NP prepared using PLGA (F1), 5%PEG-PLGA (F4) and 
10%PEG-PLGA (F7) with insulin loading kept constant at 9% and no PVA in the secondary 
emulsion.  Results are mean ± standard deviation (n=3). 
 
Fig. 3.  In vitro release profiles of NP prepared using PLGA with insulin loading of 9% (F1), 
6% (F2) and 3% (F3), with no PVA in the secondary emulsion continuous phase.  Results are 
mean ± standard deviation (n=3). 
 
Fig. 4.  In vitro release profiles of NP prepared using 5%PEG-PLGA with insulin loading of 9% 
(F4), 6% (F5) and 3% (F6), with no PVA in the secondary emulsion continuous phase.  Results 
are mean ± standard deviation (n=3). 
 
Fig. 5.  In vitro release profiles of NP prepared using 10%PEG-PLGA with insulin loading of 
9% (F7), 6% (F8) and 3% (F9), with no PVA in the secondary emulsion continuous phase.  
Results are mean ± standard deviation (n=3). 
 
Fig. 6.  In vitro release profiles of NP prepared using 1.25% PVA (F10, F12 and F14) and 
2.50% PVA (F11, F13 and F15) in the secondary emulsion continuous phase with 3% insulin 
loading.  Results are mean ± standard deviation (n=3). 
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Fig. 7.  In vitro release profiles of NP prepared using homogenisation (F9) and sonication (F16) 
with no PVA in the secondary emulsion continuous phase and 3% insulin loading.  Results are 
mean ± standard deviation (n=3). 
 
Fig. 8.  Scanning electron micrographs of F9 after formulation (A) and after 7 days of in vitro 
release (B). 
 
Fig. 9.  The percentage of residual PVA on PLGA, 5% PEG-PLGA and 10% PEG-PLGA 
insulin-loaded NP.  Values are mean ± SD with n=3. *p<0.05, **p<0.01, ***p<0.001 
compared with PLGA NP. 
 
Fig. 10.  SDS-PAGE of free insulin and insulin samples released from formulation F9 & F16 
after 7 days of in vitro incubation. Molecular weight markers (lane 1); free insulin dispersed in 
PBS (lane 2); insulin released from F9 (lane 3) and insulin released from F16 (lane 4). 
 
Fig. 11. Effects of free insulin and insulin NP (F9) on blood glucose concentrations in insulin-
deficient type I diabetic NIH Swiss mice expressed as a time-resolved plot (A and B) and AUC 
data (C). Blood glucose concentrations were measured prior to and after intraperitoneal 
injection of free insulin or insulin NP (25 U/kg bw) in insulin-deficient type I diabetic mice for 
24 hours. Values are mean ± SEM for 6 mice.  
 
Fig. 12. Effects of insulin and insulin NP (F9) on plasma insulin concentrations in insulin-
deficient type I diabetic NIH Swiss mice expressed as line graph (A) and AUC data (B). Plasma 
insulin concentrations were measured prior to and after intraperitoneal injection of insulin or 
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insulin NP (25U/kg bw) in insulin-deficient type I diabetic mice for 24 h. Values are mean 
±SEM for 6 mice. **P < 0.01, ***P < 0.001 compared with free insulin.  
 
